Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer (original) (raw)

• American Cancer Society. Cancer Facts & Figures 2006, [online] (2009).
• Ferlay, J. et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 18, 581–592 (2007).
  CAS PubMed Google Scholar
• Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687–1717 (2005).
• Goldhirsch, A. et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann. Oncol. 18, 1133–1144 (2007).
  CAS PubMed Google Scholar
• Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747–752 (2000).
  CAS PubMed Google Scholar
• Sørlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869–10874 (2001).
  PubMed PubMed Central Google Scholar
• Sledge, G. W. et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an Intergroup trial (E1193). J. Clin. Oncol. 21, 588–592 (2003).
  PubMed Google Scholar
• Chan, S. et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J. Clin. Oncol. 17, 2341–2354 (1999).
  CAS PubMed Google Scholar
• Bria, E. et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer 106, 2337–2344 (2006).
  CAS PubMed Google Scholar
• De Laurentiis, M. et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J. Clin. Oncol. 26, 44–53 (2008).
  CAS PubMed Google Scholar
• Ferguson, T., Wilcken, N., Vagg, R., Ghersi, D. & Nowak, A. K. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database of Systematic Reviews, Issue 4. Art. No.:CD004421. doi:10.1002/14651858.CD004421.pub2 (2007).
• Desmedt, C. et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin. Cancer Res. 14, 5158–5165 (2008).
  CAS PubMed Google Scholar
• Wirapati, P. et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 10, R65 (2008).
  PubMed PubMed Central Google Scholar
• Sotiriou, C. & Pusztai, L. Gene-expression signatures in breast cancer. N. Engl. J. Med. 360, 790–800 (2009).
  CAS PubMed Google Scholar
• Sotiriou, C. et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl Acad. Sci. USA 100, 10393–10398 (2003).
  CAS PubMed PubMed Central Google Scholar
• Paik, S. et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24, 3726–3734 (2006).
  CAS PubMed Google Scholar
• Albain, K. et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814, INT0100). Abstract #10 presented at the San Antonio Breast Cancer Symposium (2007).
• Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817–2826 (2004).
  CAS PubMed Google Scholar
• Ravdin, P. M. in Advances in Breast Cancer Management 2nd edn (eds Gradishar, W. J. & Wood, W. C.) 55–62 (Springer, New York, 2008).
  Google Scholar
• Berry, D. A. et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295, 1658–1667 (2006).
  CAS PubMed PubMed Central Google Scholar
• [No authors listed] Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 352, 930–942 (1998).
• Bonadonna, G. & Valagussa, P. Dose–response effect of adjuvant chemotherapy in breast cancer. N. Engl. J. Med. 304, 10–15 (1981).
  CAS PubMed Google Scholar
• Bonadonna, G., Valagussa, P., Moliterni, A., Zambetti, M. & Brambilla, C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N. Engl. J. Med. 332, 901–906 (1995).
  CAS PubMed Google Scholar
• Goldhirsch, A., Colleoni, M., Coates, A. S., Castiglione-Gertsch, M. & Gelber, R. D. Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFs alike? The International Breast Cancer Study Group (IBCSG). Ann. Oncol. 9, 489–493 (1998).
  CAS PubMed Google Scholar
• Engelsman, E. et al. “Classical” CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group phase III trial (10808). Eur. J. Cancer 27, 966–970 (1991).
  CAS PubMed Google Scholar
• Levine, M. N. et al. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J. Clin. Oncol. 23, 5166–5170 (2005).
  CAS PubMed Google Scholar
• Poole, C. J. et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N. Engl. J. Med. 355, 1851–1862 (2006).
  CAS PubMed Google Scholar
• Hutchins, L. F. et al. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup protocol INT-0102. J. Clin. Oncol. 23, 8313–8321 (2005).
  CAS PubMed Google Scholar
• Fumoleau, P. et al. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. J. Clin. Oncol. 21, 298–305 (2003).
  CAS PubMed Google Scholar
• Bonneterre, J. et al. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J. Clin. Oncol. 23, 2686–2693 (2005).
  CAS PubMed Google Scholar
• Bastholt, L. et al. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. J. Clin. Oncol. 14, 1146–1155 (1996).
  CAS PubMed Google Scholar
• Fisher, B. et al. Two months of doxorubicin–cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J. Clin. Oncol. 8, 1483–1496 (1990).
  CAS PubMed Google Scholar
• Levine, M. N. et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 16, 2651–2658 (1998).
  CAS PubMed Google Scholar
• [No authors listed] Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicenter trial. Italian Multicenter Breast Study with Epirubicin. J. Clin. Oncol. 6, 976–982 (1988).
• [No authors listed] A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group. J. Clin. Oncol. 6, 679–688 (1988).
• Henderson, I. C. et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J. Clin. Oncol. 21, 976–983 (2003).
  CAS PubMed Google Scholar
• Buzdar, A. U. et al. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin. Cancer Res. 8, 1073–1079 (2002).
  CAS PubMed Google Scholar
• Joensuu, H. et al. adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 354, 809–820 (2006).
  CAS PubMed Google Scholar
• Jones, S. E. et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J. Clin. Oncol. 24, 5381–5387 (2006).
  CAS PubMed Google Scholar
• Mamounas, E. P. et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J. Clin. Oncol. 23, 3686–3696 (2005).
  CAS PubMed Google Scholar
• Martin, M. et al. Adjuvant docetaxel for node-positive breast cancer. N. Engl. J. Med. 352, 2302–2313 (2005).
  CAS PubMed Google Scholar
• Evans, T. R. et al. 5-year outcome for women randomised in a phase III trial comparing doxorubicin (A) and cyclophosphamide (C) with doxorubicin and docetaxel (D) as primary medical therapy of breast cancer: an Anglo-Celtic Cooperative Oncology Group Study [abstract]. J. Clin. Oncol. 26 (Suppl.), a540 (2008).
  Google Scholar
• Mavroudis, D. et al. Randomized phase III trial comparing the sequential administration of docetaxel followed by epirubicin plus cyclophosphamide versus FE75C as adjuvant chemotherapy in axillary lymph node-positive breast cancer [abstract]. J. Clin. Oncol. 26 (Suppl.), a521 (2008).
  Google Scholar
• Roché, H. et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J. Clin. Oncol. 24, 5664–5671 (2006).
  PubMed Google Scholar
• Gianni, L. et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J. Clin. Oncol. 27, 2474–2481 (2009).
  CAS PubMed Google Scholar
• Bianco, A. R. et al. Sequential epirubicin–docetaxel–CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial [abstract]. J. Clin. Oncol. 24 (Suppl.), aLBA520 (2006).
  Google Scholar
• Francis, P. et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02–98 randomized trial. J. Natl Cancer Inst. 100, 121–133 (2008).
  CAS PubMed Google Scholar
• Nitz, U. et al. Interim results of Intergroup EC-Doc Trial: a randomized multicenter phase III trial comparing adjuvant CEF/CMF to EC-docetaxel in patients with 1–3 positive lymph nodes [abstract]. J. Clin. Oncol. 26 (Suppl.), a515 (2008).
  Google Scholar
• Fountzilas, G. et al. Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Ann. Oncol. 16, 1762–1771 (2005).
  CAS PubMed Google Scholar
• Burnell, M. J. et al. Cyclophosphamide, epirubicin and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer. J. Clin. Oncol. doi:10.1200/JCO.2009.22.1077 (2009).
• Ellis, P. et al. Preliminary results of the UK Taxotere as Adjuvant Chemotherapy (TACT) Trial. Abstract #78 presented at the San Antonio Breast Cancer Symposium (2007).
• Citron, M. L. et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol. 21, 1431–1439 (2003).
  CAS PubMed Google Scholar
• Hudis, C. et al. Five year follow-up of INT C9741: dose-dense (DD) chemotherapy (CRx) is safe and effective. Abstract #41 presented at the San Antonio Breast Cancer Symposium (2005).
• Winer, E. P. et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B trial 9342. J. Clin. Oncol. 22, 2061–2068 (2004).
  CAS PubMed Google Scholar
• Verrill, M. W. et al. Anglo-Celtic IV: first results of a UK national cancer research network randomised phase 3 pharmacogenetic trial of weekly versus 3 weekly paclitaxel in patients with locally advanced or metastatic breast cancer (ABC) [abstract]. J. Clin. Oncol. 25 (Suppl.), aLBA1005 (2007).
  Google Scholar
• Seidman, A. D. et al. CALGB 9840: phase III study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (S) 3 h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2-positive MBC and randomized for T in HER2-normal MBC [abstract]. J. Clin. Oncol. 22 (Suppl.), a512 (2004).
  Google Scholar
• Harvey, V. et al. Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J. Clin. Oncol. 24, 4963–4970 (2006).
  CAS PubMed Google Scholar
• Jones, S. E. et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J. Clin. Oncol. 23, 5542–5551 (2005).
  CAS PubMed Google Scholar
• Sparano, J. A. et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N. Engl. J. Med. 358, 1663–1671 (2008).
  CAS PubMed PubMed Central Google Scholar
• Green, M. C. et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J. Clin. Oncol. 23, 5983–5992 (2005).
  CAS PubMed Google Scholar
• Bear, H. D. et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project protocol B-27. J. Clin. Oncol. 24, 2019–2027 (2006).
  CAS PubMed Google Scholar
• Loesch, D. M. et al. A randomized, multicenter phase III trial comparing doxorubicin + cyclophosphamide followed by paclitaxel or doxorubicin + paclitaxel followed by weekly paclitaxel as adjuvant therapy for high-risk breast cancer [abstract]. J. Clin. Oncol. 25 (Suppl.), a517 (2007).
  Google Scholar
• Sørlie, T. Molecular classification of breast tumors: toward improved diagnostics and treatments. Methods Mol. Biol. 360, 91–114 (2007).
  PubMed Google Scholar
• Carey, L. A. et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res. 13, 2329–2334 (2007).
  CAS PubMed Google Scholar
• Fan, C. et al. Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med. 355, 560–569 (2006).
  CAS PubMed Google Scholar
• Pusztai, L. et al. Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen-receptor positive breast cancer. J. Clin. Oncol. 26, 4679–4683 (2008).
  PubMed Google Scholar
• Loi, S. et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J. Clin. Oncol. 25, 1239–1246 (2007).
  CAS PubMed Google Scholar
• Stewart, L. A. & Parmar, M. K. Meta-analysis of the literature or of individual patient data: is there a difference? Lancet 341, 418–422 (1993).
  CAS PubMed Google Scholar
• Duchateau, L. et al. Individual patient- versus literature-based meta-analysis of survival data: time to event and event rate at a particular time can make a difference, an example based on head and neck cancer. Control. Clin. Trials 22, 538–547 (2001).
  CAS PubMed Google Scholar
• Andre, F. et al. Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis. J. Clin. Oncol. 26, 2636–2643 (2008).
  CAS PubMed Google Scholar
• Hayes, D. F. et al. HER2 and response to paclitaxel in node-positive breast cancer. N. Engl. J. Med. 357, 1496–1506 (2007).
  CAS PubMed Google Scholar
• Rodríguez-Lescure, A. et al. Subgroup analysis of GEICAM 9906 trial comparing six cycles of FE90C (FEC) to four cycles of FE90C followed by 8 weekly paclitaxel administrations (FECP): relevance of HER2 and hormonal status (HR) [abstract]. J. Clin. Oncol. 25 (Suppl.), a10598 (2007).
  Google Scholar
• Jones, S. et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735. J. Clin. Oncol. 27, 1177–1183 (2009).
  CAS PubMed Google Scholar
• Kostopoulos, I. et al. Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Breast Cancer Res. Treat. 96, 251–261 (2006).
  CAS PubMed Google Scholar
• Harris, L. et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 25, 5287–5312 (2007).
  CAS PubMed Google Scholar
• Jacquemier, J. et al. Identification of a basal-like subtype and comparative effect of epirubicin-based chemotherapy and sequential epirubicin followed by docetaxel chemotherapy in the PACS 01 breast cancer trial: 33 markers studied on tissue-microarrays (TMA) [abstract]. J. Clin. Oncol. 24 (Suppl.), a509 (2006).
  Google Scholar
• Pusztai, L. Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. Ann. Oncol. 18 (Suppl. 12), xii15–xii20 (2007).
  PubMed Google Scholar
• Mechetner, E. et al. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin. Cancer Res. 4, 389–398 (1998).
  CAS PubMed Google Scholar
• Trock, B. J., Leonessa, F. & Clarke, R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J. Natl Cancer Inst. 89, 917–931 (1997).
  CAS PubMed Google Scholar
• Carlson, R. W. et al. A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): a trial of the Eastern Cooperative Oncology Group. Cancer Invest. 24, 677–681 (2006).
  CAS PubMed Google Scholar
• Hasegawa, S. et al. Mutational analysis of the class I β-tubulin gene in human breast cancer. Int. J. Cancer 101, 46–51 (2002).
  CAS PubMed Google Scholar
• Maeno, K. et al. Mutation of the class I β-tubulin gene does not predict response to paclitaxel for breast cancer. Cancer Lett. 198, 89–97 (2003).
  CAS PubMed Google Scholar
• Monzo, M. et al. Paclitaxel resistance in non-small-cell lung cancer associated with β-tubulin gene mutations. J. Clin. Oncol. 17, 1786–1793 (1999).
  CAS PubMed Google Scholar
• Noguchi, S. Predictive factors for response to docetaxel in human breast cancers. Cancer Sci. 97, 813–820 (2006).
  CAS PubMed Google Scholar
• Bernard-Marty, C. et al. Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study. Clin. Breast Cancer 3, 341–345 (2002).
  CAS PubMed Google Scholar
• Paradiso, A. et al. Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann. Oncol. 16 (Suppl. 4), iv14–iv19 (2005).
  PubMed Google Scholar
• Hamilton, A. et al. A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923. Clin. Breast Cancer 1, 233–240 (2000).
  CAS PubMed Google Scholar
• Kim, S. J. et al. High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer. Clin. Cancer Res. 11, 8425–8430 (2005).
  CAS PubMed Google Scholar
• Sjöström, J. et al. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer. Clin. Cancer Res. 6, 3103–3110 (2000).
  PubMed Google Scholar
• Rutgers, E. J., Meijnen, P., Bonnefoi, H. & European Organization for Research and Treatment of Cancer Breast Cancer Group. Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group. Breast Cancer Res. 6, 165–169 (2004).
  PubMed PubMed Central Google Scholar
• Anand, S., Penrhyn-Lowe, S. & Venkitaraman, A. R. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to taxol. Cancer Cell 3, 51–62 (2003).
  CAS PubMed Google Scholar
• Herbst, R. S. et al. Multicenter, randomized study of docetaxel versus docetaxel plus oblimersen in patients previously treated for non-small cell lung cancer (NSCLC): B1–06 [abstract B1–06]. J. Thorac. Oncol. 2 (Suppl. 4), s335 (2007).
  Google Scholar
• Rouzier, R. et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc. Natl Acad. Sci. USA 102, 8315–8320 (2005).
  CAS PubMed PubMed Central Google Scholar
• Andre, F. et al. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin. Cancer Res. 13, 2061–2067 (2007).
  CAS PubMed Google Scholar
• Pusztai, L. et al. Evaluation of microtubule associated protein tau expression as prognostic and predictive marker in the NSABP-B 28 randomized clinical trial [abstract]. J. Clin. Oncol. 27, 4287–4292 (2009).
  CAS PubMed PubMed Central Google Scholar
• Gianni, L. et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J. Clin. Oncol. 23, 7265–7277 (2005).
  CAS PubMed Google Scholar
• Dressman, H. K. et al. Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin. Cancer Res. 12, 819–826 (2006).
  CAS PubMed Google Scholar
• Chang, J. C. et al. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J. Clin. Oncol. 23, 1169–1177 (2005).
  CAS PubMed Google Scholar
• Ayers, M. et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J. Clin. Oncol. 22, 2284–2293 (2004).
  CAS PubMed Google Scholar
• Chang, J. C. et al. Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Res. Treat. 108, 233–240 (2008).
  CAS PubMed Google Scholar
• Slamon, D. et al. Role of anthracycline-based therapy in the adjuvant treatment of breast cancer: efficacy analyses determined by molecular subtypes of the disease. Abstract #13 presented at San Antonio Breast Cancer Symposium (2007).
• Freedman, O. C., Zimmermann, C. & Clemons, M. J. Interpreting the results of clinical trials of cancer chemotherapy: the importance of reporting concurrent supportive care [abstract]. Cancer Res. 69 (Suppl. 2), a6138 (2009).
  Google Scholar
• Martín, M. et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann. Oncol. 17, 1205–1212 (2006).
  PubMed Google Scholar
• Martín, M. et al. Toxicity and health-related quality of life (HRQoL) in node-negative breast cancer (BC) patients (pts) receiving adjuvant treatment with TAC (docetaxel, doxorubicin, cyclophosphamide) or FAC (5-fluorouracil, doxorubicin, cyclophosphamide): impact of adding prophylactic growth factors (GF) to TAC. GEICAM Study 9805 [abstract]. J. Clin. Oncol. 23 (Suppl.), a604 (2005).
  Google Scholar
• Hopwood, P. et al. Impact on quality of life (QoL) of FEC-T compared with FEC or E-CMF: UK Taxotere as Adjuvant Chemotherapy Trial (TACT) 2-year follow-up [abstract]. J. Clin. Oncol. 26 (Suppl.) a548 (2008).
  Google Scholar
• Hopwood, P. et al. Impact on quality of life (QL) during chemotherapy (CT) of FEC-T compared to FEC or E-CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy Trial (TACT) [abstract]. J. Clin. Oncol. 23 (Suppl.), a661 (2005).
  Google Scholar
• Ahles, T. A. et al. Quality of life of long-term survivors of breast cancer and lymphoma treated with standard-dose chemotherapy or local therapy. J. Clin. Oncol. 23, 4399–4405 (2005).
  CAS PubMed Google Scholar
• Vardy, J., Rourke, S. & Tannock, I. F. Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J. Clin. Oncol. 25, 2455–2463 (2007).
  PubMed Google Scholar
• Thornton, L. M., Carson, W. E. 3rd, Shapiro, C. L., Farrar, W. B. & Andersen, B. L. Delayed emotional recovery after taxane-based chemotherapy. Cancer 113, 638–647 (2008).
  CAS PubMed Google Scholar
• Evans, T. R. et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an Anglo-Celtic Cooperative Oncology Group study. J. Clin. Oncol. 23, 2988–2995 (2005).
  CAS PubMed Google Scholar
• Bear, H. D. et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project protocol B-27. J. Clin. Oncol. 21, 4165–4174 (2003).
  CAS PubMed Google Scholar
• Goldstein, L. J. et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J. Clin. Oncol. 26, 4092–4099 (2008).
  CAS PubMed PubMed Central Google Scholar
• Del Mastro, L. et al. Cyclophosphamide, epirubicin, and 5-fluorouracil versus epirubicin plus paclitaxel in node-positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest-Mammella Intergruppo Group [abstract]. J. Clin. Oncol. 26 (Suppl.), a516 (2008).
  Google Scholar
• Martin, M. et al. Multicenter, randomized phase III study of adjuvant chemotherapy for high-risk, node-negative breast cancer comparing TAC with FAC: 5-year efficacy analysis of the GEICAM 9805 trial [abstract]. J. Clin. Oncol. 26 (Suppl.), a542 (2008).
  Google Scholar
• Martín, M. et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J. Natl Cancer Inst. 100, 805–814 (2008).
  PubMed Google Scholar
• Cognetti, F. et al. Sequential epirubicin–docetaxel–CMF as adjuvant therapy for node-positive early stage breast cancer: updated results of the TAXit216 randomized trial [abstract]. Ann. Oncol. 19 (Suppl.), a1820 (2008).
  Google Scholar
• Rastogi, P. et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project protocols B-18 and B-27. J. Clin. Oncol. 26, 778–785 (2008).
  PubMed Google Scholar
• Roche, H. H. et al. Prognostic and predictive value of HER2, PR, ER, and Ki67 in the PACS01 trial comparing epirubicin-based chemotherapy to sequential epirubicin followed by docetaxel [abstract]. J. Clin. Oncol. 23 (Suppl.), a605 (2005).
  Google Scholar
• Martín, M. et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J. Natl Cancer Inst. 100, 805–814 (2008).
  PubMed Google Scholar
• Möbus, V. J. et al. Dose-dense sequential chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamide (C) (ETC) is superior to conventional dosed chemotherapy in high-risk breast cancer patients (≥4 + LN). First results of an AGO trial [abstract]. J. Clin. Oncol. 22 (Suppl.), a513 (2004).
  Google Scholar
• Poole, C. J. et al. tAnGo: a randomized phase III trial of gemcitabine (gem) in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy (CT) for women with early-stage breast cancer (EBC) [abstract]. J. Clin. Oncol. 26 (Suppl.), a506 (2008).
  Google Scholar
• Eiermann, W. et al. BCIRG 005 main efficacy analysis: a phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC→T) in women with Her-2/neu negative axillary lymph node positive early breast cancer. Abstract #77 presented at the San Antonio Breast Cancer Symposium (2009).
• Swain, S. M. et al. NSABP B-30: definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer. Abstract #75 presented at the San Antonio Breast Cancer Symposium (2009).
• Joensuu, H. et al. Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T)→5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX trial. Abstract #82 presented at the San Antonio Breast Cancer Symposium (2009).
• Lambert-Falls, R., Deutsch, M. A., Desch, C., Zhou, K. & Perez, E. Phase III adjuvant trial of concurrent epirubicin/taxane vs sequential epirubicin/cyclophosphamide followed by taxane for node positive breast cancer [abstract]. J. Clin. Oncol. 24 (Suppl.), a573 (2006).
  Google Scholar